Growth-hormone axis research uses two main compound families: GHRH analogs that signal the pituitary, and ghrelin-receptor secretagogues. The distinction matters for study design.








GHRH analogs — Sermorelin, Tesamorelin, and CJC-1295 — mimic growth hormone-releasing hormone at its receptor. The CJC-1295 variants illustrate the design choice clearly: with DAC produces sustained signalling, while the no-DAC version (Mod GRF 1-29) is studied for shorter, pulsatile signalling. Ipamorelin works through a different door entirely, acting at the ghrelin receptor with high selectivity and minimal off-target activity in research models.
Researchers often compare sustained versus pulsatile signalling profiles, which is why both CJC variants remain in demand. Every compound here is third-party tested with a published, lot-matched COA.